The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Abstract
The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia (relapsed, resistant/refractory, or adverse genetic disease) is uncertain. The MRC AML (Medical Research Council Acute Myeloid Leukemia) Working Group designed a trial comparing fludarabine and high-dose cytosine (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE). Patients were also randomly assigned to receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 × 109/L (or for a maximum of 28 days) and all-trans retinoic acid (ATRA) for 90 days. Between 1998 and 2003, 405 patients were entered: 250 were randomly assigned between FLA and ADE; 356 to G-CSF versus no G-CSF; 362 to ATRA versus no ATRA. The complete remission rate was 61% with 4-year disease-free survival of 29%. There were no significant differences in the CR rate, deaths in CR, relapse rate, or DFS between ADE and FLA, although survival at 4 years was worse with FLA (16% versus 27%, P = .05). Neither the addition of ATRA nor G-CSF demonstrated any differences in the CR rate, relapse rate, DFS, or overall survival between the groups. In conclusion these findings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After decades of studies, the efficacy of ATRA to treat other acute myeloid leukaemia (AML) subtypes and solid tumours remains poor.”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Milligan et al, 2006
In the citing paper
“However, other phase 2 studies showed no or non-significant effects (Milligan et al, 2006; Burnett et al, 2007).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Milligan et al, 2006
Citations
Cites
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E. M., Willman, C. L., Hurd, D. D., Bennett, J. M., Blume, K. G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392301 · Cited by 607
Burnett, A. K., Goldstone, A. H., Stevens, R., Hann, I. M., Rees, J. K. H., Gray, R. G., & Wheatley, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09214-3 · Cited by 560
Self-citationPrognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., de Greef, G. E., Jacky, E., der Lelie, J. V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 510
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., & Schiffer, C. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322503 · Cited by 447
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 437
Self-citationWheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 432
Self-citationAcute promyelocytic leukemia: evolving therapeutic strategies
Tallman, M. S., Nabhan, C., Feusner, J. H., & Rowe, J. M. (2002) · Blood · doi:10.1182/blood.v99.3.759 · Cited by 395
Research works printed but not linked: 1
- Visani G, Tosi P, Zinzani PL, et al. FLAG: an effective and tolerable protocol for the treatment of “poor-risk” acute myeloid leukemia. Leukemia. 1994;8: 1842-1846.
Cited by
Sorted by citations
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationInduction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML
Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., Najima, Y., Takagi, S., Aoki, Y., Wake, A., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1607 · Cited by 433
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D. L. P., Helgason, G. V., & Copland, M. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 365
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F. R., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 307
Metadata
- Authors
- Milligan, D. W., Wheatley, K., Littlewood, T., Craig, J. I. O., Burnett, A. K., & for the NCRI Haematological Oncology Clinical Studies Group
- Affiliations
- John Radcliffe Hospital (GB)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-06-15
- Volume
- 107
- Issue
- 12
- Pages
- 4614-4622
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1984229644
- Cited by
- 141
- References
- 49
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 11 · 2015: 10 · 2014: 7 · 2013: 8 · 2012: 8
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- high-risk acute myeloid leukemia, fludarabine, cytarabine, daunorubicin, etoposide, filgrastim, granulocyte colony-stimulating factor, all-trans retinoic acid, reinduction chemotherapy, complete remission, disease-free survival, relapse
- MeSH terms
- Filgrastim, Adolescent, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Daunorubicin, Etoposide, Female, Humans, Male, Middle Aged, Recombinant Proteins, Remission Induction, Retrospective Studies, Risk Factors, Tretinoin, Leukemia, Myeloid, Acute, Survival Rate, Granulocyte Colony-Stimulating Factor, Treatment Outcome, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
